Vibegron for the treatment of overactive bladder symptoms
AssigneeSumitomo Pharma Co., Ltd.
InventorsPaul N. MUDD, JR., Cornelia HAAG-MOLKENTELLER, Jihao ZHOU
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to a method of treating overactive bladder symptoms in men with benign prostatic hyperplasia comprising orally administering to a subject in need thereof an amount of from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day.
Claims19
-40. (canceled)
A method of treating at least one overactive bladder symptom selected from the group consisting of urge urinary incontinence, urgency, urinary frequency, nocturia, and a combination thereof in a human male subject with benign prostatic hyperplasia, the method comprising orally administering to the subject an amount of from 50 mg to 100 mg of vibegron per day.
A method of preparing an oral dosage form comprising vibegron and at least one pharmaceutically acceptable excipient, wherein the method comprises wet granulation, wet milling, fluid bed drying, dry milling, lubrication, tableting, or aqueous film coating.
Dependencies are inferred from the claim text.